Personalising Tirzepatide Maintenance

A Lancet item titled Personalising maintenance after tirzepatide weight loss is a letter, not a new clinical trial^[1]. The primary trial behind the maintenance question is SURMOUNT-MAINTAIN. It tested three paths after 60 weeks of open-label tirzepatide: continue the maximum tolerated dose, reduce to 5 mg, or switch to placebo. Both tirzepatide groups maintained more of the original weight reduction through week 112 than the placebo group^[2].

That result supports continued treatment as a general strategy. It does not establish a formula for choosing an individual's maintenance dose. The trial compared two active strategies with withdrawal, while a separate semaglutide cohort explored response-based dosing in routine digital care. Those designs answer different questions.

What SURMOUNT-MAINTAIN tested

SURMOUNT-MAINTAIN was a phase 3b trial at 20 US sites. It enrolled 441 adults with obesity, or overweight plus at least one weight-related condition, and excluded people with diabetes. Everyone first received open-label tirzepatide for 60 weeks. At that point, 378 participants were randomized in a 3:3:2 ratio to continue their maximum tolerated dose of 10 mg or 15 mg, reduce to 5 mg, or switch to placebo for another 52 weeks^[2]. The trial administered these doses under a protocol. They are not instructions for personal use.

At week 112, the model-based change from the original baseline was minus 21.9% in the maximum-tolerated-dose group, minus 16.6% in the 5 mg group, and minus 9.9% in the placebo group. The estimated treatment difference versus placebo was 12.0 percentage points for the maximum tolerated dose and 6.6 points for 5 mg, with p values below 0.0001^[2]. The lower active dose therefore produced an intermediate group average. It was not equivalent to continuing the higher dose.

The protocol also allowed rescue tirzepatide from week 84 when a participant regained more than half of the weight previously lost. Rescue treatment was used by 8% of the maximum-tolerated-dose group, 25% of the 5 mg group, and 67% of the placebo group^[2]. Gastrointestinal events were the most common adverse events with tirzepatide. They were mostly mild to moderate and occurred mainly during dose escalation.

Why this is not a dose-finding answer

Randomization makes the between-group comparison useful, but the study population had already completed 60 weeks of tirzepatide and reached a weight plateau. The result applies to that selected point in treatment. It does not show that every person who has lost weight should remain on the same dose, reduce at the same time, or use a fixed weight threshold to decide.

SURMOUNT-4 provides a related withdrawal result with a different design. After a 36-week open-label lead-in, 670 participants were randomized either to continue tirzepatide or switch to placebo. From randomization to week 88, the continued-treatment group lost another 5.5%, while the placebo group regained 14.0%. At week 88, 89.5% of those continuing treatment had maintained at least 80% of their initial loss, compared with 16.6% after withdrawal^[4]. Two withdrawal trials now point in the same direction: stopping treatment leads to more regain on average.

Neither trial randomized people among multiple maintenance plans based on side effects, appetite, cost, body composition, treatment goals, or other clinical factors. SURMOUNT-MAINTAIN compared one reduced dose with continuation and placebo. It cannot identify the lowest effective dose for a specific person.

What the semaglutide cohort adds

The Lancet letter also sits alongside a different kind of evidence: a retrospective Danish cohort of 2,694 adults enrolled in a commercial digital program that combined personalized semaglutide dosing with intensive behavioral therapy. The program adjusted dosing according to weight change, hunger, satiety, and tolerability. At week 64, the model-estimated mean weight change was minus 16.7%, and the mean weekly semaglutide dose was 1.08 mg^[3].

That cohort was observational, not randomized. Only 465 of 2,694 participants remained active at week 64, 80% lacked a recorded weight at the primary endpoint, and weight and medication data were self-reported. Participants paid for the program and were motivated to engage in behavioral treatment. The authors also reported that the study was sponsored by Embla, while several authors were current or former Embla employees^[3]. Those limits prevent the study from proving that lower or personalized dosing caused the reported weight loss.

The cohort does show what a treat-to-target service can look like in practice: repeated monitoring and adjustment rather than one maintenance plan for everyone. It cannot be transferred from semaglutide to tirzepatide as if the medicines, populations, and support programs were interchangeable.

What the current label says

Current US prescribing information identifies Zepbound as a GIP and GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in eligible adults^[5]. The label tells clinicians to consider treatment response and tolerability when selecting a maintenance dose. The tirzepatide regulation record tracks the medicine's status in the jurisdictions we cover.

A labeled maintenance range is not evidence that dose changes can be made without clinical review. The trials reported group averages and monitored adverse events under formal protocols. Personalization remains a clinician-patient decision informed by response, tolerability, medical history, and the approved label.

What we still do not know

The evidence does not yet define a validated algorithm for stepping down tirzepatide after weight loss. We also lack randomized comparisons of response-guided maintenance strategies, long follow-up beyond the trial period, and enough evidence for people who stop because of adverse effects, cost, pregnancy planning, or another clinical reason. Future trials would need prespecified adjustment rules and outcomes that include regain, tolerability, body composition, and quality of life.

The practical readout is narrow. Continued tirzepatide maintained more weight reduction than withdrawal, and reducing to 5 mg produced an intermediate average result in SURMOUNT-MAINTAIN. That supports maintenance treatment while leaving the individual dosing question open.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.